文献速递泌尿男性生殖肿瘤

根治性前列腺切除术后高危前列腺特异性抗原复发前列腺癌挽救性放疗联合恩扎卢胺或安慰剂的II期随机研究:SALV-ENZA试验

Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial.
PubMed 文献 · J Clin Oncol · 2022-11-11

该研究纳入根治性前列腺切除术后生化复发前列腺癌患者,随机接受挽救性放疗联合恩扎卢胺160 mg每日一次或安慰剂治疗6个月。恩扎卢胺组无PSA进展生存期显著优于安慰剂组(HR 0.42,95%CI 0.19-0.92,P=0.031),2年无PSA进展生存率分别为84%和66%。

要点

  • 恩扎卢胺联合挽救性放疗较单用放疗显著改善无PSA进展生存(HR 0.42,95%CI 0.19-0.92,P=0.031)。
  • 2年无PSA进展生存率恩扎卢胺组84% vs 安慰剂组66%。
  • pT3和R1亚组从恩扎卢胺获益更明显,交互作用P值分别为0.019和0.023。

核心结论

  • 根治性前列腺切除术后PSA复发高危前列腺癌患者接受6个月恩扎卢胺单药联合挽救性放疗是安全的,且较单用挽救性放疗延迟PSA进展。
  • 恩扎卢胺对远处转移或生存的影响目前尚不清楚。

研究设计与样本

  • 随机、双盲、II期、安慰剂对照、多中心研究(ClinicalTrials.gov标识:NCT02203695)。
  • 根治性前列腺切除术后生化复发前列腺癌患者随机(1:1)分配,按中心、手术切缘状态(R0 vs R1)、挽救治疗前PSA(≥0.5 vs <0.5 ng/mL)和病理Gleason评分(7 vs 8-10)分层。
  • 患者接受恩扎卢胺160 mg每日一次或匹配安慰剂治疗6个月;研究药物治疗2个月后,对前列腺床(不放疗盆腔淋巴结)行外照射放疗(66.6-70.2 Gy)。
  • 主要终点为意向治疗人群的无PSA进展生存期;次要终点包括放疗野内局部复发时间、无转移生存期和安全性(不良事件频率和严重程度)。
  • 共86例患者随机分配,中位随访34个月(范围0-52个月)。

主要发现

  • 恩扎卢胺组无PSA进展生存期显著优于安慰剂组(HR 0.42;95%CI 0.19-0.92;P=0.031),2年无PSA进展生存率分别为84% vs 66%。
  • 亚组分析显示恩扎卢胺在pT3患者中获益(HR 0.22;95%CI 0.07-0.69),而pT2患者HR 1.54(95%CI 0.43-5.47),交互作用P=0.019。
  • R1患者中恩扎卢胺HR 0.14(95%CI 0.03-0.64),R0患者HR 1.00(95%CI 0.36-2.76),交互作用P=0.023。
  • 次要终点事件数不足,无法分析。
  • 最常见不良事件为1-2级疲乏(恩扎卢胺组65% vs 安慰剂组53%)和尿频(恩扎卢胺组40% vs 安慰剂组49%)。

关键数值与推荐

  • 主要终点无PSA进展生存期:恩扎卢胺组 vs 安慰剂组 HR 0.42(95%CI 0.19-0.92;P=0.031)。
  • 2年无PSA进展生存率:恩扎卢胺组84% vs 安慰剂组66%。
  • pT3亚组HR 0.22(95%CI 0.07-0.69)vs pT2亚组HR 1.54(95%CI 0.43-5.47),交互作用P=0.019。
  • R1亚组HR 0.14(95%CI 0.03-0.64)vs R0亚组HR 1.00(95%CI 0.36-2.76),交互作用P=0.023。
  • 中位挽救治疗前PSA为0.3 ng/mL(范围0.06-4.6 ng/mL);56/86例(65%)为pT3,39/86例(45%)Gleason评分8-10,43/86例(50%)切缘阳性(R1)。

临床怎么用

  • 对于根治性前列腺切除术后PSA复发的高危前列腺癌患者,挽救性放疗联合6个月恩扎卢胺单药治疗是安全的,且较单用挽救性放疗延迟PSA进展。
  • 恩扎卢胺对远处转移或生存的影响目前尚不清楚。

局限性

  • 次要终点事件数不足,无法分析。
  • 恩扎卢胺对远处转移或生存的影响目前尚不清楚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We sought to investigate whether enzalutamide (ENZA), without concurrent androgen deprivation therapy, increases freedom from prostate-specific antigen (PSA) progression (FFPP) when combined with salvage radiation therapy (SRT) in men with recurrent prostate cancer after radical prostatectomy (RP). PATIENTS AND METHODS: Men with biochemically recurrent prostate cancer after RP were enrolled into a randomized, double-blind, phase II, placebo-controlled, multicenter study of SRT plus ENZA or placebo (ClinicalTrials.gov identifier: NCT02203695). Random assignment (1:1) was stratified by center, surgical margin status (R0 v R1), PSA before salvage treatment (PSA ≥ 0.5 v < 0.5 ng/mL), and pathologic Gleason sum (7 v 8-10). Patients were assigned to receive either ENZA 160 mg once daily or matching placebo for 6 months. After 2 months of study drug therapy, external-beam radiation (66.6-70.2 Gy) was administered to the prostate bed (no pelvic nodes). The primary end point was FFPP in the intention-to-treat population. Secondary end points were time to local recurrence within the radiation field, metastasis-free survival, and safety as determined by frequency and severity of adverse events. RESULTS: Eighty-six (86) patients were randomly assigned, with a median follow-up of 34 (range, 0-52) months. Trial arms were well balanced. The median pre-SRT PSA was 0.3 (range, 0.06-4.6) ng/mL, 56 of 86 patients (65%) had extraprostatic disease (pT3), 39 of 86 (45%) had a Gleason sum of 8-10, and 43 of 86 (50%) had positive surgical margins (R1). FFPP was significantly improved with ENZA versus placebo (hazard ratio [HR], 0.42; 95% CI, 0.19 to 0.92; P = .031), and 2-year FFPP was 84% versus 66%, respectively. Subgroup analyses demonstrated differential benefit of ENZA in men with pT3 (HR, 0.22; 95% CI, 0.07 to 0.69) versus pT2 disease (HR, 1.54; 95% CI, 0.43 to 5.47; Pinteraction = .019) and R1 (HR, 0.14; 95% CI, 0.03 to 0.64) versus R0 disease (HR, 1.00; 95% CI, 0.36 to 2.76; Pinteraction = .023). There were insufficient secondary end point events for analysis. The most common adverse events were grade 1-2 fatigue (65% ENZA v 53% placebo) and urinary frequency (40% ENZA v 49% placebo). CONCLUSION: SRT plus ENZA monotherapy for 6 months in men with PSA-recurrent high-risk prostate cancer after RP is safe and delays PSA progression relative to SRT alone. The impact of ENZA on distant metastasis or survival is unknown at this time.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Tran PT, Lowe K, Tsai HL, et al. Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial. J Clin Oncol. 2022. PMID: 36367998. doi:10.1200/JCO.22.01662

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。